-
Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1 Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-11 Stetson Van Matre, Saaimatul Huq, Lokesh Akana, Daniel E. Eldridge, Oscar Zuniga, Henrique Rodrigues, Adam R. Wolfe
Overcoming radioresistance is a critical challenge in pancreatic ductal adenocarcinoma (PDAC). Our study investigates the targeting of Cyclin-dependent kinase-1 (CDK1) through genetic and pharmaceutical inhibition to radiosensitize PDAC cells. Mass spectrometry and phosphoproteomics were used to analyze engineered radiation-resistant PDAC cell lines (MIA PaCa-2 and PANC-1) compared to parental controls
-
Brachial plexopathy following stereotactic body radiation therapy in apical lung malignancies: A dosimetric pooled analysis of individual patient data Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-08 Hui Bai, Xiao-Feng Wang, Yi-Han Xu, Nicholas G Zaorsky, Huan-Huan Wang, Geng-Min Niu, Jia-Cheng Li, Yang Dong, Jun-Yi Li, Lu Yu, Mei-Feng Chen, Xiao-Tong Lu, Zhi-Yong Yuan, Ji-Long Yang, Mao-Bin Meng
The aim of this study is to establish dosimetric constraints for the brachial plexus at risk of developing grade ≥ 2 brachial plexopathy in the context of stereotactic body radiation therapy (SBRT). Individual patient data from 349 patients with 356 apical lung malignancies who underwent SBRT were extracted from 5 articles. The anatomical brachial plexus was delineated following the guidelines provided
-
Association of the combined stereotactic radiosurgery and embolization strategy and long-term outcomes in brain arteriovenous malformations with a volume >10 ml: A nationwide multicenter observational prospective cohort study Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-07 Zhipeng Li, Jun Zhang, Heze Han, Dezhi Gao, Hengwei Jin, Li Ma, Ruinan Li, Anqi Li, Haibin Zhang, Kexin Yuan, Ke Wang, Qinghui Zhu, Chengzhuo Wang, Debin Yan, Junlin Lu, Yukun Zhang, Yang Zhao, Youxiang Li, Shibin Sun, Yuanli Zhao, Yu Chen, Xiaolin Chen, Registry of Multimodality Treatment for Brain Arteriovenous Malformation in Mainland China (MATCH)
To assess the long-term outcome of large brain arteriovenous malformations (AVMs) (volume > 10 ml) underwent combined embolization and stereotactic radiosurgery (E+SRS) versus SRS alone. Patients were recruited from a nationwide multicenter prospective collaboration registry (MATCH study, August 2011–August 2021) and categorized into E+SRS and SRS alone cohorts. Propensity score-matched survival analysis
-
RSPO3 regulates the radioresistance of Non-Small cell lung cancer cells via NLRP3 Inflammasome-Mediated pyroptosis Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-07 Hongbin Li, Jialin Zhang, Boyi Yu, Tiantian Yang, Bingtao Liu, Feifei Li, Xiaodong Jin, Qiang Li
Radioresistance is a significant challenge in the radiotherapy of non-small cell lung cancer (NSCLC). This study aimed to investigate the role of R-spondin 3 (RSPO3) in regulating NSCLC radioresistance. RNA sequencing was performed to analyze genes that are differentially expressed in radioresistant NSCLC cell lines. RSPO3 overexpression and knockdown experiments were conducted to assess its impact
-
-
A patient-specific auto-planning method for MRI-guided adaptive radiotherapy in prostate cancer Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-06 Xiaonan Liu, Xinyuan Chen, Deqi Chen, Yuxiang Liu, Hong Quan, Linrui Gao, Lingling Yan, Jianrong Dai, Kuo Men
Fast and automated generation of treatment plans is desirable for magnetic resonance imaging (MRI)-guided adaptive radiotherapy (MRIgART). This study proposed a novel patient-specific auto-planning method and validated its feasibility in improving the existing online planning workflow. Data from 40 patients with prostate cancer were collected retrospectively. A patient-specific auto-planning method
-
Clinical implementation of deep learning robust IMPT planning in oropharyngeal cancer patients: A blinded clinical study Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-06 Ilse G. van Bruggen, Marije van Dijk, Minke J. Brinkman-Akker, Fredrik Löfman, Johannes A. Langendijk, Stefan Both, E.W. Korevaar
This study aimed to evaluate the plan quality of our deep learning-based automated treatment planning method for robustly optimized intensity-modulated proton therapy (IMPT) plans in patients with oropharyngeal carcinoma (OPC). The assessment was conducted through a retrospective and prospective study, blindly comparing manual plans with deep learning plans. A set of 95 OPC patients was split into
-
Multidisciplinary team quality improves the survival outcomes of locally advanced rectal cancer patients: A post hoc analysis of the STELLAR trial Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-05 Huiying Ma, Haoyue Li, Tongzhen Xu, Yuanhong Gao, Shixin Liu, Wenling Wang, Lichun Wei, Xishan Wang, Liming Jiang, Yihebali Chi, Jinming Shi, Jiacheng Shuai, Shuangmei Zou, Yong Cai, Yuan Zhu, Guanghui Cheng, Hongyan Zhang, Xin Wang, Suyu Zhu, Jun Wang, Gaofeng Li, Jialin Yang, Kuan Zhang, Ningning Lu, Hui Fang, Shulian Wang, Yexiong Li, Haitao Zhou, Yuan Tang, Jing Jin
We sought to determine the association between multidisciplinary team (MDT) quality and survival of patients with locally advanced rectal cancer. In a post hoc analysis of the randomized phase III STELLAR trial, 464 patients with distal or middle-third, clinical tumor category cT3-4 and/or regional lymph node-positive rectal cancer who completed surgery were evaluated. Disease-free survival (DFS) and
-
Analysis of re-recurrent rectal cancer after curative treatment of locally recurrent rectal cancer Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-05 F. Piqeur, L. Coolen, S. Nordkamp, D.M.J. Creemers, R.H.N. Tijssen, A.G.J. Neggers-Habraken, H.J.T. Rutten, J. Nederend, C.A.M. Marijnen, J.W.A. Burger, H.M.U. Peulen
Substantiating data guiding clinical decision making in locally recurrent rectal cancer (LRRC) is lacking, specifically in target volume (TV) definition for chemoradiotherapy (CRT). A case-by-case review of local re-recurrences (re-LRRC) after multimodal treatment for LRRC was performed, to determine location of re-LRRC and assess whether treatment could have been improved. All patients treated with
-
Adapting outside the box: Simulation-free MR-guided stereotactic ablative radiotherapy for prostate cancer Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-05 Jeremiah de Leon, Urszula Jelen, Madeline Carr, David Crawford, Maddison Picton, Charles Tran, Laura McKenzie, Valery Peng, Tania Twentyman, Michael G. Jameson, Vikneswary Batumalai
Magnetic resonance (MR)-guided radiotherapy (MRgRT) enhances treatment precision and adaptive capabilities, potentially supporting a simulation-free (sim-free) workflow. This work reports the first clinical implementation of a sim-free workflow using the MR-Linac for prostate cancer patients treated with stereotactic ablative radiotherapy (SABR). Fifteen patients who had undergone a prostate-specific
-
Semi-automated reproducible target transfer for cardiac radioablation – A multi-center cross-validation study within the RAVENTA trial Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-04 Stephan Hohmann, Jingyang Xie, Miriam Eckl, Melanie Grehn, Nizar Karfoul, Christian Janorschke, Roland Merten, Boris Rudic, Daniel Buergy, Evgeny Lyan, David Krug, Felix Mehrhof, Leif-Hendrik Boldt, Stefanie Corradini, Hannah Fanslau, Lena Kaestner, Adrian Zaman, Frank A. Giordano, David Duncker, Jürgen Dunst, Roland R. Tilz, Achim Schweikard, Oliver Blanck, Judit Boda-Heggemann
Stereotactic arrhythmia radioablation (STAR) is a therapeutic option for ventricular tachycardia (VT) where catheter-based ablation is not feasible or has previously failed. Target definition and its transfer from electro-anatomic maps (EAM) to radiotherapy treatment planning systems (TPS) is challenging and operator-dependent. Software solutions have been developed to register EAM with cardiac CT
-
Deep learning-assisted interactive contouring of lung cancer: Impact on contouring time and consistency Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-03 Michael J. Trimpl, Sorcha Campbell, Niki Panakis, Daniel Ajzensztejn, Emma Burke, Shawn Ellis, Philippa Johnstone, Emma Doyle, Rebecca Towers, Geoffrey Higgins, Claire Bernard, Roland Hustinx, Katherine A. Vallis, Eleanor P.J. Stride, Mark J. Gooding
To evaluate the impact of a deep learning (DL)-assisted interactive contouring tool on inter-observer variability and the time taken to complete tumour contouring. Nine clinicians contoured the gross tumour volume (GTV) using the PET-CT scans of 10 non-small cell lung cancer (NSCLC) patients, either using DL-assisted or manual contouring tools. After contouring a case using one contouring method, the
-
Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-03 Eleni Gkika, Cas Stefaan Dejonckheere, Jörg Sahlmann, Simeon Ari Barth, Tanja Schimek-Jasch, Sonja Adebahr, Markus Hecht, Matthias Miederer, Alexander Brose, Harald Binder, Jochem König, Anca-Ligia Grosu, Ursula Nestle, Andreas Rimner
The aim of this secondary analysis of the prospective randomized phase 2 PET-Plan trial (ARO-2009-09; NCT00697333) was to evaluate the impact of mediastinal tumor burden and lymphatic spread in patients with locally advanced non-small-cell lung cancer (NSCLC). All patients treated per protocol ( = 172) were included. Patients received isotoxically dose-escalated chemoradiotherapy up to a total dose
-
Call For Papers: Radiotherapy & Oncology and The Lancet Oncology collaboration Radiother. Oncol. (IF 4.9) Pub Date : 2024-09-02 Pierre Blanchard, David Collingridge
-
Pretreatment plasma osteopontin level as a marker of response to curative radiotherapy and hormonal treatment for prostate cancer Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-31 Beata Smolska-Ciszewska, Jolanta Mrochem-Kwarciak, Katarzyna Karczmarczyk, Regina Deja, Rafał Suwiński
Osteopontin is a known marker for tumour hypoxia with relevance for the outcome of radiotherapy. We analysed the plasma concentration of OPN in prostate cancer patients receiving RT with or without ADT to evaluate OPN as a potential marker of treatment response. Between 2012 and 2014, 274 patients with prostate cancer qualifying for RT were enrolled to the study. SCADT received 34.3 % of patients,
-
2489: Endothelial senescence primes aggressiveness of glioblastoma cells after radiotherapy Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Hala Awada, Charlotte Degorre, Anne Christin Parplys, Ophélie Renoult, Kerstin Borgman, Laure Sabatier, Claire Pecqueur, François Paris
-
18: Secondary analysis of JCOG1008: Frequency and risk factors associated with the hypothyroidism Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Hidetoshi Shimizu, Takeshi Kodaira, Naomi Kiyota, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuuji Hirayama, Yusuke Onozawa, Naoki Nishio, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Keita Sasaki, Ryo Kitabayashi, Satoshi Ishikura, Yasumasa Nishimura, Makoto Tahara
-
11: Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Astrid E. Persson, Elisabeth Kjellén, Hans Garmo, Gabriel Adrian, Pär Stattin, Anders Widmark, Per Nilsson, Adalsteinn Gunnlaugsson
-
10: Preservation of vision with fully fractionated stereotactic RT for posterior choroidal melanoma. Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Claire Phillips, Elena Ungureanu, Mathias Bressel, Roderick O'Day, John McKenzie, Daniel McKay, Haris Ahmad, Lotte Fog, Joseph Sia, Fred Chen, William Campbell
-
3628: Bridging the evidence gap: From physics and technology innovations to clinical practice Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 David I. Thwaites
-
3625: Rehabilitation after gynaecological radiotherapy Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Aoife Nolan
-
3622: Single-cell analysis of lung responses to radiation injury Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Charles Fouillade
-
3621: ESTRO-ACROP recommendations for evidence-based use of antiandrogen deprivation therapy in combination with external-beam radiotherapy in prostate cancer Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Constantinos Zamboglou
-
3613: ESTRO-ACROP consensus guideline for the management of radiodermatitis Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Elizabeth Forde, Ludwig van den Berghe, Monica Buijs, Antonella Cardone, Jacqueline Daly, Pierfrancesco Franco, Naman Julka-Anderson, Wolfgang Lechner, Laure Marignol, Heather Nisbeth, Giulia Marvaso, Anita O'Donovan, Nicola S. Russell, Philipp Scherer
-
3611: ESTRO-ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Piet Dirix, Alan Dal Pra, Vincent Khoo, Christian Carrie, Cesare Cozzarini, Valérie Fonteyne, Pirus Ghadjar, Alfonso Gomez-Iturriaga, Nina-Sophie Schmidt-Hegemann, Valeria Panebianco, Almudena Zapatero, Alberto Bossi, Thomas Wiegel
-
3606: The economist, for efficiency and care improvement Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Alexander Fabian
-
-
3596: The optimisation Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Daniella Elisabet Oestergaard
-
3581: Novel unconventional technologies for hypofractionation Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Yolanda Prezado
-
3577: Refresher and Innovations in Gynaecological Brachytherapy: A RTT's Perspective Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Bernd Wisgrill
-
3563: AI for automation of brachytherapy planning Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Anton Bouter
-
3552: Working within the framework of MDR in clinical radiotherapy Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Eva Onjukka
-
3551: Which breast cancer patients need more nodal radiotherapy? Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 David J. Dodwell
-
3550: What does quality in education practice and research look like? Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Daniel W. Golden
-
3549: What are the major bottlenecks for getting it into clinics? Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Edmond Sterpin
-
3548: Virtual patients for clinical trials Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Ehsan Abadi
-
-
-
-
3538: The surgeon, for organ-sparing treatment approaches Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Francesco Bussu
-
3536: The role of proton radiotherapy in the treatment of oesophageal cancer Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Christina Muijs
-
3535: The role of brachytherapy (interventional radiotherapy) dose escalation for organ preservation in head & neck cancer Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Ashwini Budrukkar
-
3532: The physcisist's perspective Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Daniela Thorwarth
-
3532: The oncologist for immunotherapy Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Silke Tribius
-
3531: The NARLAL II trial: First results on loco-regional control in stage 3 NSCLC Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Tine Schytte, Charlotte Kristiansen, Ane Appelt, Azza Khalil, Carsten Brink, Christina Maria Lutz, Ditte Slot Moeller, Erland Sande, Filippa Sundbye, Gitte Persson, Lone Hoffmann, Lotte Holm Land, Lotte Victoria Rogg, Mette Poehl, Mikkel Lund, Morten Nielsen, Nina Levin, olfred Hansen, Rune Slot Thing, Tarje Halvorsen, Tine Bjoern Nielsen, Torben Schjødt Hansen, Vilde Haakensen, Wiviann Ottosson, Marianne
-
3520: APBI with 3D-CRT vs. WBI: primary endpoint results of the prospective randomised phase 3 IRMA trial Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Bruno Meduri, Antonella Baldissera, Cinzia Iotti, Luc J.E.E. Scheijmans, Marcel R. Stam, Salvatore Parisi, Liesbeth J. Boersma, Eveline Koiter, Mariacarla Valli, Luciano Scandolaro, Dianne Busz, Helen Westenberg, Selena Ciabatti, Patrizia Giacobazzi, Maria P. Ruggieri, Antoine Engelen, Tindara Munafo', Karolien Verhoeven, Roberto Vicini, Riccardo Cuoghi Costantini, Roberto D'Amico, Frank Lohr, Elisa
-
3514: The elderly patient unfit for cisplatin: Then what? Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Alexander Rühle
-
3513: The "poor responder" after radiotherapy for SCCHN from radiobiological point of view Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Ingeborg Tinhofer-Keilholz
-
3512: Technological developments and future prospects Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Daniela Thorwarth
-
3511: Technical advancements tailoring dose and volume Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Kari Tanderup
-
3510: What every physicist should know about commissioning TG-43- and model-based treatment planning systems in brachytherapy Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Javier Vijande
-
3508: Targeting aerobic glycolysis and mitochondrial respiration to overcome radioresistance Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Paul N. Span
-
3506: Survivorship and the role of the MDT in breast cancer rehabilitation post-radiotherapy Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Karen Patrice Molan
-
-
3504: Statistics for radiation therapy insiders: What to use and when? Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Ivan R. Vogelius
-
3501: Social inequality and other socioeconomic factors affecting treatment in head and neck cancer care: Can we actually do something? Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Maja Halgren Olsen
-
3498: Sexual support and survivorship in prostate cancer Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 William Kinnaird
-
-
3490: Risk-adapted and response-adapted strategies for stage 3 NSCLC Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Andrea Riccardo Filippi
-
3488: Recent advances in dermatooncology – ESTRO view Radiother. Oncol. (IF 4.9) Pub Date : 2024-08-30 Agata Rembielak